Yesterday, Pablo Belmonte, Newmanbrain CEO, in the event LSI USA 2025 unveiled one of its most awaited innovations: Theia, a non-invasive fNIR technology powered by artificial intelligence (AI), specifically designed to accurately assess mild cognitive impairment (MCI).
What is LSI USA?
LSI USA is the Emerging Medtech Summit organized by Life Science Intelligence (LSI). It gathers over 1500 worldwide healthcare leaders, investors, and strategies to discuss the most groundbreaking innovations in health tech. This year’s event in Dana Point (California) aims to connect venture capital and private equity investors with innovative companies. The summit aims to facilitate business opportunities and provide a forum to exchange insights and foster partnerships.
What is Theia and How Does it Work?
Theia is a portable tool that uses fNIR (Near Infrared Spectroscopy) to objectively assess Mild Cognitive Impairment (MCI). The assessment takes less than 20 minutes and provides healthcare professionals with a cognitive evaluation report in real time. This technology opens the door for early clinical interventions.
The Importance of Early Detection
Early detection of cognitive impairment is crucial, especially considering that diseases like dementia have a devastating impact on both individuals and healthcare systems. In the United States, dementia-related costs exceed $207 billion annually, highlighting the urgent need for more effective and accessible diagnostic solutions.
The ability to identify cognitive decline in its early stages not only improves treatment opportunities but also opens up new possibilities for research and the development of more effective interventions.
Connecting in Dana Point, California
Currently, the LSI USA team is in Dana Point, California, attending key events related to cognitive health. They will be present until March 21, offering a unique opportunity to connect with industry professionals and share more details about Theia and its applications.
Joining Forces for Better Cognitive Health
At Newmanbrain our vision is to enable timely interventions, advance research on brain-drug interactions, and ultimately transform the landscape of cognitive health.